Immutep Ltd has released a press release.
TACTI-004 phase III trial enrolment continues at robust pace
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
- Immutep enters into Strategic Collaboration with Dr. Reddy's
- Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
- New data presentation from AIPAC-003 Phase II for SABCS
- Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
Later from Immutep
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
- Positive Update on IMP761 Phase 1
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Quarterly Activities Report Q2 FY26
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep